Table Info

Table 2.

Possible building blocks for the diagnosis of axSpA—part 2: later diagnosis

Nr	Feature	Assessment	Decision
1	Limitation of spinal mobility	BASMI and thoracic excursion	Score > 3
2	Limitation of function	BASFI	Score > 3
3	Structural X-ray changes in the spine	X-ray, mSASSS (syndesmophytes, ankylosis)	Not applicable

axSpA: axial spondyloarthritis; Nr: number; BASMI: Bath Ankylosing Spondylitis Metrology Index; BASFI: Bath Ankylosing Spondylitis Functional Index; mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score

Declarations

Author contributions

JB: Conceptualization, Investigation, Writing—original draft. DP: Writing—review & editing, Investigation, Validation. All authors read and approved the submitted version.

Conflicts of interest

Jürgen Braun, who is the Associate Editor of Exploration of Musculoskeletal Diseases, had no involvement in the decision-making or the review process of this manuscript. The other authors declare that they have no conflicts of interest.

Ethical approval

According to the local guidelines, since this is a review and not a study, no ethical approval is needed in Germany.

Consent to participate

All patients in the University Hospital B. Franklin in Berlin give informed consent.

Consent to publication

All patients in the University Hospital B. Franklin in Berlin give informed consent.

Availability of data and materials

The raw data supporting the conclusions of this manuscript can be requested from the corresponding author for appropriate reasons.

Funding

Not applicable.

Copyright

References

Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–90. [DOI] [PubMed]

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73–84. [DOI] [PubMed]

Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59:iv47–57. [DOI] [PubMed] [PMC]

Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921–5. [DOI] [PubMed]

Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med. 2015;163:409–16. [DOI] [PubMed]

Heijde Dvd, Molto A, Ramiro S, Braun J, Dougados M, Gaalen FAv, et al. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis. 2024;83:547–49. [DOI] [PubMed]

Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 1994;37:1039–45. [DOI] [PubMed]

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–93. [DOI] [PubMed]

Linden Svd, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8. [DOI] [PubMed]

10.

Rudwaleit M, Heijde Dvd, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83. [DOI] [PubMed]

11.

Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39–47. [DOI] [PubMed] [PMC]

12.

Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and diagnosis of axial spondyloarthritis—what is the clinically relevant differenc? J Rheumatol. 2015;42:31–8. [DOI] [PubMed]

13.

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford). 2019;58:1634–38. [DOI] [PubMed]

14.

Navarro-Compán V, Benavent D, Capelusnik D, Heijde Dvd, Landewé RB, Poddubnyy D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2023;[Epub ahead of print]. [DOI] [PubMed]

15.

Olivieri I, D’Angelo S, Padula A, Leccese P, Palazzi C. Spondyloarthritis with onset after age 45. Curr Rheumatol Rep. 2013;15:374. [DOI] [PubMed]

16.

Schmidt CO, Günther K, Goronzy J, Albrecht K, Chenot J, Callhoff J, et al. Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63:415–25. German. [DOI] [PubMed]

17.

Tubergen Av, Heuft-Dorenbosch L, Schulpen G, Landewé R, Wijers R, Heijde Dvd, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis. 2003;62:519–25. [DOI] [PubMed] [PMC]

18.

Rudwaleit M, Jurik AG, Hermann KA, Landewé R, Heijde Dvd, Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520–7. [DOI] [PubMed]

19.

Hermann KA, Baraliakos X, Heijde DMFMvd, Jurik A, Landewé R, Marzo-Ortega H, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71:1278–88. [DOI] [PubMed]

20.

Lambert RGW, Bakker PAC, Heijde Dvd, Weber U, Rudwaleit M, Hermann KG, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis. 2016;75:1958–63. [DOI] [PubMed]

21.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, et al. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann Rheum Dis. 2019;78:1550–58. [DOI] [PubMed]

22.

Baraliakos X, Østergaard M, Lambert RG, Eshed I, Machado PM, Pedersen SJ, et al. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Ann Rheum Dis. 2022;81:1243–51. [DOI] [PubMed]

23.

Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, et al. Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years. Ann Rheum Dis. 2020;79:186–92. [DOI] [PubMed]

24.

Winter Jd, Hooge Md, Sande Mvd, Jong Hd, Hoeven Lv, Koning Ad, et al. Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis Rheumatol. 2018;70:1042–8. [DOI] [PubMed] [PMC]

25.

Poddubnyy D, Weineck H, Diekhoff T, Redeker I, Gobejishvili N, Llop M, et al. Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. Rheumatology (Oxford). 2020;59:3798–806. [DOI] [PubMed]

26.

Bennett AN, McGonagle D, O’Connor P, Hensor EMA, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58:3413–8. [DOI] [PubMed]

27.

Baraliakos X, Ghadir A, Fruth M, Kiltz U, Redeker I, Braun J. Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists ‘Evaluations With Radiologists’ Findings. Arthritis Rheumatol. 2021;73:800–5. [DOI] [PubMed]

28.

Poddubnyy D, Diekhoff T, Baraliakos X, Hermann KGA, Sieper J. Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography? Ann Rheum Dis. 2022;81:1486–90. [DOI] [PubMed]

29.

Diekhoff T, Eshed I, Radny F, Ziegeler K, Proft F, Greese J, et al. Choose wisely: imaging for diagnosis of axial spondyloarthritis. Ann Rheum Dis. 2022;81:237–42. [DOI] [PubMed] [PMC]

30.

Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58–67. [DOI] [PubMed]

31.

Khan MA, Khan MK. Diagnostic value of HLA-B27 testing in ankylosing spondylitis and Reiter’s syndrome. Ann Intern Med. 1982;96:70–6. [DOI] [PubMed]

32.

Braun A, Gnann H, Saracbasi E, Grifka J, Kiltz U, Letschert K, et al. Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatology (Oxford). 2013;52:1418–24. [DOI] [PubMed]

33.

Ziade NR. HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps. BMC Musculoskelet Disord. 2017;18:280. [DOI] [PubMed] [PMC]

34.

Li Z, Wu X, Leo PJ, Guzman ED, Akkoc N, Breban M, et al.; TCRI AS Group. Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Ann Rheum Dis. 2021;80:1168–74. [DOI] [PubMed] [PMC]

35.

Vastesaeger N, Heijde Dvd, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973–81. [DOI] [PubMed] [PMC]

36.

Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47–53. [DOI] [PubMed]

37.

Spoorenberg A, Heijde Dvd, Klerk Ed, Dougados M, Vlam Kd, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999;26:980–4. [PubMed]

38.

Landewé R, Nurminen T, Davies O, Baeten D. A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’. Arthritis Res Ther. 2018;20:209. [DOI] [PubMed] [PMC]

39.

Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613–4. [PubMed]

40.

Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006;54:569–78. [DOI] [PubMed]

41.

Sieper J, Heijde Dvd, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68:784–8. [DOI] [PubMed]

42.

Weisman MH, Witter JP, Reveille JD. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. Ann Rheum Dis. 2013;72:369–73. [DOI] [PubMed] [PMC]

43.

Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol. 1995;34:1074–7. [DOI] [PubMed]

44.

Rudwaleit M, Heijde Dvd, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63:535–43. [DOI] [PubMed] [PMC]

45.

McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352:1137–40. [DOI] [PubMed]

46.

Heijde Dvd, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al.; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582–91. [DOI] [PubMed]

47.

Inman RD, Jr JCD, Heijde Dvd, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12. [DOI] [PubMed]

48.

Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447–51. [DOI] [PubMed]

49.

Redeker I, Siegmund B, Ghoreschi K, Pleyer U, Callhoff J, Hoffmann F, et al. The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Ther Adv Musculoskelet Dis. 2020;12:1759720X20972610. [DOI] [PubMed] [PMC]

50.

Ez-Zaitouni Z, Hilkens A, Gossec L, Berg IJ, Landewé R, Ramonda R, et al. Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. Arthritis Res Ther. 2017;19:118. [DOI] [PubMed] [PMC]

51.

Amor B. Response to treatment as an aid to diagnosis. Rev Rhum Mal Osteoartic. 1992;59:3S–6S. [PubMed]

52.

Baraliakos X, Bergmann E, Tsiami S, Redeker I, Braun J. A Good Response to Nonsteroidal Antiinflammatory Drugs Does Not Discriminate Patients With Longstanding Axial Spondyloarthritis From Controls With Chronic Back Pain. J Rheumatol. 2024;51:250–6. [DOI] [PubMed]

53.

Jones GT, Bennett AN, Sengupta R, Machado PM, Marzo-Ortega H, Aucott L, et al. OA14 Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis. Rheumatology. 2023;62:kead104.014. [DOI]

54.

Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis. 2009;68:1466–9. [DOI] [PubMed]

55.

Braun J, Landewé R, Hermann KA, Han J, Yan S, Williamson P, et al.; ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646–52. [DOI] [PubMed]

56.

Kiltz U, Baraliakos X, Regel A, Bühring B, Braun J. Causes of pain in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2017;35:S102–7. [PubMed]

57.

Boel A, Molto A, Heijde Dvd, Ciurea A, Dougados M, Gensler LS, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78:1545–9. [DOI] [PubMed]

58.

Deodhar A, Strand V, Kay J, Braun J. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75:791–4. [DOI] [PubMed]

59.

Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60:946–54. [DOI] [PubMed]

60.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392:134–44. [DOI] [PubMed]

61.

Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694–8. [PubMed]

62.

Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5. [PubMed]

63.

Braun J, Baraliakos X, Buehring B, Kiltz U, Fruth M. Imaging of axial spondyloarthritis. New aspects and differential diagnoses. Clin Exp Rheumatol. 2018;36:35–42. [PubMed]

64.

Baraliakos X, Listing J, Recke Avd, Braun J. The natural course of radiographic progression in ankylosing spondylitis–evidence for major individual variations in a large proportion of patients. J Rheumatol. 2009;36:997–1002. [DOI] [PubMed]

65.

Ramiro S, Heijde Dvd, Tubergen Av, Stolwijk C, Dougados M, Bosch Fvd, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455–61. [DOI] [PubMed]

66.

Braun J, Baraliakos X, Buehring B, Fruth M, Kiltz U. Differential diagnosis of axial spondyloarthritis-axSpA mimics. Z Rheumatol. 2019;78:31–42. German. [DOI] [PubMed]

67.

Braun J. Why are the classification and diagnosis of axial spondyloarthritis sometimes so difficult? Rheumatology (Oxford). 2024;63:264–6. [DOI] [PubMed]

68.

Li Z, Linden SMvd, Khan MA, Baumberger H, Zandwijk Hv, Khan MK, et al. Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter. RMD Open. 2022;8:e002302. [DOI] [PubMed] [PMC]

69.

Heijde Dvd, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019;58:388–400. [DOI] [PubMed] [PMC]

70.

Bruin Fd, Koning Ad, Berg Rvd, Baraliakos X, Braun J, Ramiro S, et al. Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Ann Rheum Dis. 2018;77:371–77. [DOI] [PubMed]

71.

Heijde Dvd, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018;77:699–705. [DOI] [PubMed] [PMC]

72.

Molnar C, Scherer A, Baraliakos X, Hooge Md, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77:63–9. [DOI] [PubMed] [PMC]

73.

Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070–7. [DOI] [PubMed]

74.

Baraliakos X, Østergaard M, Poddubnyy D, Heijde Dvd, Deodhar A, Machado PM, et al. Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study. Arthritis Rheumatol. 2022;74:L15.

75.

Baraliakos X, Listing J, Buschmann J, Recke Avd, Braun J. A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. Arthritis Rheum. 2012;64:1127–33. [DOI] [PubMed]

76.

Bogduk N. Degenerative joint disease of the spine. Radiol Clin North Am. 2012;50:613–28. [DOI] [PubMed]

77.

Baraliakos X, Regel A, Kiltz U, Menne H, Dybowski F, Igelmann M, et al. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford). 2018;57:1541–7. [DOI] [PubMed]

78.

Pengel LHM, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ. 2003;327:323. [DOI] [PubMed] [PMC]

79.

Hayden JA, Dunn KM, Windt DAvd, Shaw WS. What is the prognosis of back pain? Best Pract Res Clin Rheumatol. 2010;24:167–79. [DOI] [PubMed]

80.

Helliwell PS, Hetthen J, Sokoll K, Green M, Marchesoni A, Lubrano E, et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum. 2000;43:865–71. [DOI] [PubMed]

81.

Alonso JCT, Perez AR, Castrillo JMA, Garcia JB, Noriega JLR, Larrea CL. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30:245–50. [DOI] [PubMed]

82.

Proft F, Lüders S, Hunter T, Luna G, Rodriguez VR, Protopopov M, et al. Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study. Ann Rheum Dis. 2022;81:1534–40. [DOI] [PubMed] [PMC]

83.

Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14:363–71. [DOI] [PubMed]

84.

Braun J, Coates LC. Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases? RMD Open. 2023;9:e003063. [DOI] [PubMed] [PMC]

85.

Braun J, Landewé RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? Ann Rheum Dis. 2022;81:466–8. [DOI] [PubMed]

86.

Coates LC, Baraliakos X, Blanco FJ, Blanco-Morales EA, Braun J, Chandran V, et al. The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status? Arthritis Care Res (Hoboken). 2021;73:856–60. [DOI] [PubMed]

87.

Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023;9:e003102. [DOI] [PubMed] [PMC]

88.

Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505. [DOI] [PubMed]

89.

Hanson A, Brown MA. Genetics and the Causes of Ankylosing Spondylitis. Rheum Dis Clin North Am. 2017;43:401–14. [DOI] [PubMed] [PMC]

90.

Khan MA. An Update on the Genetic Polymorphism of HLA-B*27 With 213 Alleles Encompassing 160 Subtypes (and Still Counting). Curr Rheumatol Rep. 2017;19:9. [DOI] [PubMed]

91.

López-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens. 1995;45:169–76. [DOI] [PubMed]

92.

D’Amato M, Fiorillo MT, Galeazzi M, Martinetti M, Amoroso A, Sorrentino R. Frequency of the new HLA-B*2709 allele in ankylosing spondylitis patients and healthy individuals. Dis Markers. 1995;12:215–7. [DOI] [PubMed]

93.

Garrido-Mesa J, Brown MA. T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. Curr Rheumatol Rep. 2022;24:398–410. [DOI] [PubMed] [PMC]

94.

Braun J, Märker-Hermann E, Rudwaleit M, Sieper J. HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis. Ann Rheum Dis. 2024;[Epub ahead of print]. [DOI] [PubMed]

95.

Li Z, Khan MK, Linden SMvd, Winkens B, Villiger PM, Baumberger H, et al. HLA-B27, axial spondyloarthritis and survival. Ann Rheum Dis. 2023;82:1558–67. [DOI] [PubMed]

96.

Braun J, Baraliakos X, Bülow R, Schmidt CO, Richter A. Striking sex differences in magnetic resonance imaging findings in the sacroiliac joints in the population. Arthritis Res Ther. 2022;24:29. [DOI] [PubMed] [PMC]

97.

Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, et al. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis. 2016;75:874–8. [DOI] [PubMed]

98.

Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, et al. In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. Ann Rheum Dis. 2018;77:470–2. [DOI] [PubMed]

99.

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34. [DOI] [PubMed]

100.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3–17. [DOI] [PubMed] [PMC]

101.

Molto A, López-Medina C, Bosch FEVd, Boonen A, Webers C, Dernis E, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021;80:1436–44. [DOI] [PubMed] [PMC]

102.

Kiltz U, Heijde Dvd, Boonen A, Cieza A, Stucki G, Khan MA, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74:830–5. [DOI] [PubMed] [PMC]

103.

Kiltz U, Braun J. Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial” by Molto et al. Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial” by Molto et al. Ann Rheum Dis. 2023;82:e229. [DOI] [PubMed]

104.

Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385:142–52. [DOI] [PubMed]

105.

Kiltz U, Landewé RBM, Heijde Dvd, Rudwaleit M, Weisman MH, Akkoc N, et al. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2020;79:193–201. [DOI] [PubMed] [PMC]